A 2-part, Phase 1-2 controlled, open-label, randomized study in patients with
platinum-resistant recurrent ovarian cancer. In Part 1, patients will receive SGI-110 and
carboplatin. The optimum dose will be identified in Part 1 based on safety and efficacy.
In Part 2, patients will be randomized to receive the dose identified in Part 1 plus
carboplatin or one of three treatment of choice at the discretion of the investigator. The
treatment of choice consists of topotecan, pegylated liposomal doxorubicin, or paclitaxel.
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Bristol Heamatology and Oncology Centre, Bristol BS2 8ED, United Kingdom
St. James Univesity Hospital - St. James Institute of Oncology, Leeds LS9 7TF, United Kingdom
Univesity College Hospital, London CET NW1 2PG, United Kingdom
Cambridge University Hospitals NHS Foundation and Trust, London EC1V 4AD, United Kingdom
Imperial College Health Care NHS Trust-Garry Weston Centre, London W12 0NN, United Kingdom
Mount Vernon Cancer Centre, Middlesex HA6 2RN, United Kingdom
Royal Marsden Foundation Trust, Sutton SM2 5PT, United Kingdom
Tom Baker Cancer Centre, Calgary, Alberta T2N 4N2, Canada
Norris Comprehensive Cancer Center- University of Southern California, Los Angeles, California 90033, United States
University of Florida Shands Cancer Center, Gainesville, Florida 32610, United States
Georgia Health Sciences University, Augusta, Georgia 30912, United States
University of Chicago, Chicago, Illinois 60637, United States
Melvin and Bren Simon Cancer Center- Indiana University, Indianapolis, Indiana 46202, United States
Women's Cancer Care, Covington, Louisiana 70433, United States
Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland 21231, United States
Dana Farber Cancer Institute, Boston, Massachusetts 02115, United States
Island Gynecologic Oncology, Brightwaters, New York 11718, United States
Duke Cancer Institute- Duke University Medical Center, Durham, North Carolina 27710, United States
University of Cincinnati Cancer Institute, Cincinnati, Ohio 45267, United States
Juravinski Cancer Centre, Hamilton, Ontario L8V 5C2, Canada
Princess Margaret Hospital, Toronto, Ontario M5G 2M9, Canada
CHUM Gynecologie-Oncologie, Notre Dame Hospital, Montreal, Quebec H2L 4M1, Canada
Mary Crowley Medical Research Center, Dallas, Texas 75201, United States
Inova Fairfax Hospital, Falls Church, Virginia 22042, United States